TScan Therapeutics
TCRX
81 hedge funds and large institutions have $51.8M invested in TScan Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 32 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
6% less capital invested
Capital invested by funds: $55.4M → $51.8M (-$3.57M)
8.44% less ownership
Funds ownership: 76.73% → 68.29% (-8.4%)
12% less funds holding
Funds holding: 92 → 81 (-11)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$3.61M |
| 2 |
Renaissance Technologies
New York
|
+$899K |
| 3 |
Millennium Management
New York
|
+$576K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$486K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$400K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.83M |
| 2 |
BlackRock
New York
|
-$3.34M |
| 3 |
CC
Checkpoint Capital
San Francisco,
California
|
-$2.78M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$915K |
| 5 |
State Street
Boston,
Massachusetts
|
-$891K |
TCRX Hedge Fund Activity: Q2 2025 in Review
81 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2025, worth a combined $51.8M — down 6.4% from $55.4M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of TCRX and 21 opened new positions — a net loss of 11 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $3.61M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.83M sold.
- 81 institutional investors held TScan Therapeutics (TCRX) as of Q2 2025, down from 92 in Q1 2025.
- Funds reported $51.8M of TScan Therapeutics stock for Q2 2025, down 6.4% quarter-over-quarter.
- 21 funds opened new TScan Therapeutics positions in Q2 2025 and 32 closed out, a net change of -11 holders.
- The largest TScan Therapeutics buyer in Q2 2025 was Lynx1 Capital Management, an estimated $3.61M added.
- The largest TScan Therapeutics seller in Q2 2025 was Adage Capital Partners, an estimated $4.83M sold.
Based on aggregated 13F filings for Q2 2025.